Th1 - CD11c⁺ B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis

Kimitoshi Kimura, MD, PhD,1,2,3 Youwei Lin, MD,1,3,4 Hiromi Yamaguchi, BD,1 Wakiro Sato, MD, PhD,1,3 Daiki Takewaki, MD,1,3 Misako Minote, MD,1,3 Yoshimitsu Doi, MD, PhD,1,3 Tomoko Okamoto, MD, PhD,3,4 Ryosuke Takahashi, MD, PhD,2 Takayuki Kondo, MD, PhD,5 and Takashi Yamamura, MD, PhD1,3

Objective: Although plasmapheresis is a treatment option for patients with autoimmune neurological diseases, treatment response varies greatly among patients. The main objective of this study was to find out if biological/immune traits correlate with a beneficial response.

Methods: We thoroughly analyzed immune phenotypes in paired blood samples from a cohort of 31 patients with multiple sclerosis before and after plasmapheresis, in parallel with clinical evaluation of treatment response.

Results: The frequency of IFN-γ⁺ Th1 cells was persistently higher in those who obtained benefit from plasmapheresis (responders) than nonresponders. The Th1 cell frequency before plasmapheresis provided a high predictive value for beneficial response, achieving area under the curve (AUC) of 0.902. Plasmapheresis treatment decreased inflammation-related gene expressions in Th1 cells. Meanwhile, IFNG expression in Th1 cells positively correlated with the frequency of CD11c⁺ B cells, of which a pathogenic role has been suggested in several autoimmune diseases. In line with this, in vitro experiments showed that CD11c⁺ B cells would increase in response to exogenous IFN-γ compared to IL-4, and secrete high amounts of IgG. B cell receptor analysis indicated that clonal expansion of CD11c⁺ B cells takes place in patients with multiple sclerosis. Interestingly, CD11c⁺ B cells, which showed unique gene expression profile, decreased after plasmapheresis treatment along with all the immunoglobulin subsets in the circulation.

Interpretation: Taken together, we postulate that Th1 cell - CD11c⁺ B cell axis is involved in treatment response to plasmapheresis, giving us clues to better understanding of complicated pathogenesis of autoimmune diseases, and getting closer to a personalized therapy.

Plasmapheresis (PP) is a procedure which removes immunoglobulins and other humoral factors from the plasma. It has been shown to effectively reduce inflammation, thereby controlling symptoms and signs of various autoimmune neurological diseases, including multiple sclerosis, neuromyelitis optica spectrum disorders, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis.¹ With regard to multiple sclerosis, sham-controlled trials that were conducted in the last century showed that plasma exchange (PLEX) significantly improved the disease severity score.²,³ More recently, immunoadsorption plasmapheresis (IAPP), which selectively removes immunoglobulin but spares most of other constituents including albumin, showed a similar or even better outcome regarding the rate for beneficial treatment response.⁴–⁸ Nevertheless, it should be
noted that one to two thirds of the patients did not obtain significant benefits from PP in these studies. To overcome the problem of low response rate, it appears to be a rational approach to identify a key immunological pathway involved in the responsiveness to PP.

Prior studies showed that pathology of multiple sclerosis lesions comprises four distinct patterns, presumably corresponding to heterogeneous inflammatory processes. Among the 4 patterns, pattern II is characterized by prominent antibody deposition along with T cell infiltration. It appears that PP is particularly beneficial for patients with pattern II lesions, supporting the prevailing hypothesis that the removal of pathogenic immunoglobulin is a key therapeutic mechanism. However, it is still a challenge to predict response to PP in individual cases.

Here, we show that patients who benefit from IAPP are characterized by a higher frequency of T helper (Th) 1 cells in the peripheral blood before the treatment than nonresponders, which appears to have a significant value for prediction of PP responses. The expression levels of inflammation-related genes in Th1 cells, including IFNG, decreased after IAPP treatment. Notably, IFNG expression in Th1 cells positively correlated with the frequency of CD11c⁺ B cells, which are transcriptionally and clonally distinct from other B cell populations, and highly potent in producing antibodies presumably involved in the pathogenesis. These results allow us to postulate that the effect of PP could be attributed not only to removal of antibodies but also to phenotypic change of Th1 cells, which would reduce CD11c⁺ B cells with potential pathogenicity. Collectively, this study sheds light on the heterogeneity in the immunopathogenesis of multiple sclerosis, and provides a new mechanistic insight into the IAPP treatment, which appears to be more complex than removing disease-relevant antibodies.

Methods

Subjects

Demographics of the patients with multiple sclerosis and healthy control subjects are described in the Table. All the patients were treated at National Center Hospital of Neurology and Psychiatry, Japan, from 2017 to 2019. McDonald criteria 2010 was used to make the diagnosis of multiple sclerosis. We have been aware that there is a group of patients who can be treated successfully with plasmapheresis even a while after the last relapse or even when they are already in a progressive state. Therefore, we recruited such patients as well as some patients soon after a relapse. Patients in relapse were defined as those within 1 month after the last relapse in this study. All the patients had a history of insufficient response to treatment with high-dose steroids. All the patients were treated with IAPP or double-filtration plasmapheresis (DFPP) for 4 to 7 times in one treatment course. Plasmauš (Asahi Kasei Medical, Tokyo, Japan) was used for both treatments. Plasmauš OP-05 W (Asahi Kasei Medical) was used to separate plasma from cellular components. Thereafter, IAPP was performed with IMMUSORBA TR-350 (Asahi Kasei Medical), a tryptophan immobilized polyvinyl alcohol gel column, and DFPP was performed with Cascadeflo EC-20 W (Asahi Kasei Medical). Treated plasma volume was 1.5 L per session of both procedures. Then, 600–750 ml of 5% albumin was administered per session of DFPP. The blood samples were collected within 1 week before the first and after the fourth PP. The blood sample was obtained only before the treatment for one patient who was treated with DFPP. A neurologist, who was blinded to any laboratory results obtained by flow cytometer, evaluated the treatment response. The responders were defined as patients with objective clinical improvement with any change of Expanded Disability Status Scale (EDSS), including functional system scoring after the treatment, regardless of subjective evaluation. The EDSS was evaluated within 1 week before and about 1 month after PP. In the analysis of IFN-γ⁺, IL-17A⁺, and IFN-γ⁺IL-17A⁺Foxp3⁺ T cells in Figure 1, data are shown with 2 distinct dots for each of 5 patients who underwent the IAPP course twice at different time points. The absolute Th1 cell number in the peripheral blood was calculated based on the number of lymphocytes that was tested within 3 days prior to flow cytometry assay (see Fig 1D). The Ethics Committee of National Center of Neurology and Psychiatry approved the study protocol according to the Declaration of Helsinki. Written informed consent was obtained from all subjects.

Cell Preparation and Flow Cytometry

Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation, using Ficoll–Paque PLUS (GE Healthcare Bioscience, Ontario, Canada). They were stained for cell surface antigens, followed by intracellular staining using Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego CA, USA) or BD Cytofix Cytoperm Buffer (BD Bioscience, San Diego, CA, USA) according to the manufacturer’s instructions. The antibodies and isotype controls used in this study were as follows: FITC-anti-Foxp3 (PCH101; eBioscience), V500-anti-CD3 (UCHT1), V500-anti-CD4 (RPA-T4), APC-Cy7-anti-CD19 (SJ25C1), V500-anti-CD27 (M-T271), APC-H7-anti-CD45RA (HI100), PE-Cy7-anti-CD45RA (L48), AlexaFluor-488-anti-CD56 (B159), PE-anti-CD180 (G28-8), V500-anti-
FIGURE 1: IAPP responder is characterized by Th1 cell predominance. (A) Representative flow cytometry plots showing inflammatory and regulatory CD4⁺ T cells in the peripheral blood of responders and nonresponders to IAPP prior to the treatment with IAPP. (B) The frequencies of inflammatory and regulatory T cells among memory CD4⁺ T cells in the peripheral blood of healthy controls, responders, and nonresponders, before the IAPP treatment. In the 3 panels from the left for assessment of Th1, Th17, and Treg cells (IFN-γ⁺, IL-17A⁺, and IFN-γ IL-17A Foxp3⁺), data are shown with 2 distinct dots for each of 5 patients who underwent IAPP course twice. (C) The frequency of Th1 cells among memory CD4⁺ T cells was analyzed in the peripheral blood of responder and nonresponder patients to DFPP, before the treatment. (D) The absolute Th1 cell number in the peripheral blood prior to the IAPP treatment. Data are shown with 2 distinct dots for each of 3 patients who underwent the IAPP course twice. (E) No significant alterations in the frequency of each T cell subset after IAPP. (F) Receiver operating characteristic (ROC) curve based on the frequency of Th1 cells (IFN-γ⁺CD45RA⁺CD4⁺ T cells) for prediction of responders before the IAPP treatment. Th1 cell frequency of 7.02% had the highest positive likelihood ratio for prediction of responders. An unpaired was used for statistical analysis in B, C, and D, and a paired t test was used in E. Error bars represent the mean ± SD. AUC = area under the ROC curve; DFPP = double-filtration plasmapheresis; IAPP = immunoabsorption plasmapheresis. [Color figure can be viewed at www.annalsofneurology.org]
To evaluate the effect of environmental factors, CD4+ Cell Culture instructions. Cells (1 x $10^5$) from healthy controls were cultured in the presence of 125 or 250 μg/ml of fibrinogen (Merck Millipore, Darmstadt, Germany), 0.5 ng/ml of SDF-1α (Peprotech, Rocky Hill, NJ, USA), 0.2 ng/ml of GRO-α (Peprotech), or 2 ng/ml of PDGF-BB (Peprotech), for 2 days. AIM-V medium was used. To stain intracellular cytokines, cells were stimulated with 50 ng/ml of phorbol-myristate-acetate, 500 ng/ml of ionomycin, and 2 μM monensin for 4 hours just before staining. To analyze gene expression and cytokine secretion of cultured cells, they were similarly stimulated without monensin.

To analyze the secreted immunoglobulin by B cells, naive B cells from healthy controls were lysed, reverse transcribed, and pre-amplified for 18 cycles using Single Cell-to-CT Kit (Thermo Fisher Scientific, Waltham, MA, USA) and pooled primers as described below (Fluidigm, South San Francisco, CA, USA). The pre-amplified samples were then subjected to polymerase chain reaction (PCR) using TaqMan Universal PCR Master Mix (Life Technologies, Carlsbad, CA, USA) and Biomark HD System (Fluidigm) according to the manufacturer’s protocol. Target gene expression was normalized to the expression of ACTB. The primers for PCR in the analysis of Th1 cells were as follows; IFNG (forward primer [FP]: ACTGCCAGGACCATATGGAA, reverse primer [RP]: GTTTCAATATTACGGTACATCTGAA), CSF2 (FP: TGATGCGCACCGACACTAA and RP: CAAAGGGGATAAGACGACAGGAAA), STAT1 (FP: ATGCTGGCACCAGAAAGA and RP: GCTGCGACAATTGGGTCTTCAA), STAT3 (FP: GGAATATGCTGAAAGGTTGAC and RP: CCGAGGTCACAATCCATCTGCAA), STAT4 (FP: CAGTGCGGAGTTAAAGGA and RP: AGAGGCAGATCTGTGTTTCAA), TBX21 (FP: GGGCGTCACAAACAAGTTGAC and RP: CGCTGCTGTCACTCAGAATA), GATA3 (FP: CACGGTGCAAGGGTAC and RP: AGGGGATGATCATGAAGCA), ROFC (FP: CAAGACTCATGCGCAAGA and RP: TTTCCAATGCTGGCTTCAA), FOXP3 (FP: TGTGGGAGGATCAGGAAG and RP: GGGTCGCCATCTTAAGCA), IFNRR1 (FP: AAGCGGGATTTCGAGA and RP: GATATCCGATTTGACAGGA), and ACTB (FP: CCAACCGCGAGAGATGAC and RP: TAGACAGCTGGATGCAA).

To analyze gene expression of cultured CD4+ T cells, total RNA was prepared from the cultured cells using RNAeasy Kit and RNase-Free DNase Set (QIAGEN, Venlo, The Netherlands), and reverse transcribed to complementary DNA using PrimeScript RT Master Mix (Takara Bio, Kusatsu, Japan). PCR was performed using SYBR Premix Ex Taq (Takara Bio), and LightCycler 96 (Roche, Basel, Switzerland). The expression level of each mRNA was determined with normalization to ACTB. The primers for PCR in the analysis of CD4+ cells were as follows: ACTB (FP: CCAACCGCGAGAGATGAC and RP: TAGACAGCTGGATGCAA), IFNG (FP: CACGGTGCAAGGGTAC and RP: GGGTCGCCATCTTAAGCA).
ACTGCCAGGACCCCATATGTAA and RP: GTTCCATTATCCGCTACATCTGAA, STAT1 (FP: ATGCTGGCACCAGAACGAA and RP: GCTGGCACAATTTGCGGTTCGAA), STAT4 (FP: CAGTGTGAGTAAAGGAA and RP: AGAGGCA-GATCTGTGTTCGAA), TBX21 (FP: GGGCGTCACAAC-AATGTCGAC and RP: CCGTCGTTACCTCAAGGATA; Fasmac, Atsugi, Japan).

Detection of Fibrinogen, Immunoglobulin, and Other Cytokines
The concentration of fibrinogen in the plasma was determined with AssayMax Human Fibrinogen ELISA Kit (Assaypro, St. Charles, MO, USA). The concentration of immunoglobulin in the serum was determined using Antibody Isotyping 7-Plex Human ProcartaPlex Panel (Invitrogen) according to the manufacturer’s instruction. The other cytokines in the serum were measured using Bio-Plex Pro Human Cytokine Screening Panel (48-Plex; Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instruction. The cytokines included in the analysis are those for which more than 70% of the tested samples showed values within their standard range.

Next Generation Sequencing of B Cell Receptor Genes and B Cell Receptor Repertoire Analysis
B cell subsets were sorted, lysed in ISOGEN-LS (Nippon Gene, Tokyo, Japan), and further processed for B cell receptor (BCR) sequencing in Repertoire Genesis Inc. (Ibaraki, Japan). The obtained sequencing data were analyzed with a repertoire analysis software, Repertoire Genesis, which was originally developed by Repertoire Genesis Inc. The details are described in previous papers. Only the in-frame CDR3 reads that can be translated into amino acid sequences were included in the analysis. Unique reads were defined as distinct ones that have the same IgHV, IgHD, IgHJ, and IgHC and the CDR3 sequences with the same resultant amino acid sequences.

Analysis of Gene Expression Profile of B Cell Subsets
About 15,000 B cells per sample in average were sorted for nCounter analysis with GX Human Immunology V2 kit (NanoString Technologies, Seattle, WA, USA). Cell lysate was prepared with RLT buffer (QIAGEN), and used as input material, according to the manufacturer’s protocol. The data were analyzed with advanced analysis function in nSolver software. The nCounter of each RNA was normalized using the geometric mean of 11 housekeeping genes, EEF1G, RPL19, TBPI, SDHA, POLR2A, PPLA, OAZ1, G6PD, ABCF1, TUBB, and POLR1B, which were selected by nCounter algorithm. The genes, which were detected above the low count threshold level for less than 25% of the samples, were excluded from the analysis. Next, the normalized data were used for further analysis with iDEP software (version 0.90).

Statistical Analysis
Data were analyzed with Prism software (GraphPad Software, La Jolla, CA, USA) unless otherwise indicated. An unpaired or a paired t test was used to compare data from 2 groups, using Welch’s correction as appropriate. Two-way analysis of variance (ANOVA with Holm-Sidak or Dunnett’s comparison test was used to compare data from more than 2 groups, as appropriate. Pearson’s analysis was used to evaluate correlations. Differences were considered significant when the p value was <0.05.

Data Availability
The gene expression profile data of B cell subsets with nCounter system were deposited to the Gene Expression Omnibus database in National Center for Biotechnology Information (NCBI). The accession number is GSE158326.

Results
Th1 Cell Frequency in the Peripheral Blood Is Higher in PP Responders
To portray the immunological characteristics that correlate with treatment effect of PP, immune cells in the peripheral blood of patients with multiple sclerosis were analyzed before and after the treatment with IAPP. When evaluated by an objective clinical improvement based on EDSS, including functional system scoring after the treatment, 53% of the patients were judged as being IAPP responders (see the Table). The response rate was not different between patients within and more than 1 month after a relapse (75% vs 50%, p = 0.61) nor between relapsing–remitting and secondary-progressive multiple sclerosis (50% vs 67%, p = 0.71). The median EDSS changed from 4.25 (interquartile range [IQR] = 2.5) to 3.75 (IQR = 2.63) in responders to IAPP, and did not change in nonresponders (see the Table). The clinical improvement was sustained for 4.5 ± 1.6 months (mean ± SD) for the responders. The most striking immunological difference was observed in IFN-γ+CD4+ Th1 cell frequency before treatment, which was significantly higher in IAPP responders than in nonresponders (see Fig 1A, B). The same trend of a higher Th1 frequency in PP responders was observed in another cohort of patients who received DFPP (see Fig 1C). The median EDSS changed from 7 (IQR = 1.0) to 6.75 (IQR = 0.75) in responders to DFPP, and did not change in nonresponders (see the Table). The absolute Th1 cell number was also higher in
CD4+ T cells showed a tendency to be higher in responders than nonresponders before IAPP (see Fig 1D). In contrast, the frequency of IL-17A+CD4+ Th17 cells, another inflammatory Th cell, and IFN-γ IL-17A+Foxp3+CD4+ regulatory T (Treg) cells did not differ between responders and nonresponders (see Fig 1A, B). IL-4+CD4+ Th2 cells, and IL-10+CD4+ T cells showed a tendency to be higher in responders without significance (see Fig 1B). Although the frequencies of these cells were not altered after IAPP treatment (see Fig 1E), the Th1 cell frequency appeared to have a predictive value for identifying responders before starting the treatment (see Fig 1F). Th1 cell frequency of 7.02% had the highest positive likelihood ratio for prediction of responders with a sensitivity of 76.5% and a specificity of 93.3%.

Further analysis showed that the frequency of follicular helper T cells, which are specialized for mainly providing B cell help in the germinal centers, did not correlate with treatment response (Fig 2A, B). There was no difference between responders and nonresponders in the frequencies of B cell lineage groups, NKT cells, NK cells, HLADR+ NK cells, and several monocyte types (see Fig 2C–F). The treatment with IAPP did not alter the frequencies of these subsets (data not shown). As these thorough analyses indicate that a high frequency of Th1 cells has a significant predictive value for responders (see Fig 1B, F), we explored for the underlying mechanism for this intriguing observation.

### Table. Demographics of all the Participants

|                      | HC (n = 13) | Responder to IAPP (n = 16) | Nonresponder to IAPP (n = 11) | Responder to DFPP (n = 2) | Nonresponder to DFPP (n = 3) | Repertoire analysis (n = 2) | B cell gene expression analysis (n = 3) |
|----------------------|-------------|---------------------------|--------------------------------|---------------------------|-------------------------------|-----------------------------|----------------------------------------|
| Age (mean [SD])      | 42.1 [8.8]  | 46.1 [9.9]                | 42.6 [9.3]                     | 53 [0]                    | 44 [5.3]                      | 51.5 [7.8]                  | 43.7 [13.0]                           |
| M: F                 | 6: 7        | 5: 11                     | 1: 10                          | 0: 2                      | 0: 3                          | 1: 1                        | 1: 2                                   |
| Disease duration (years) (mean [SD]) | 13.3 [10.1] | 12.3 [6.3]                | 12.5 [2.1]                    | 20.7 [12.2]               | 7 [2.8]                      | 7.8 [0.6]                   | 2.5 [4.5]                             |
| EDSS (median [range]) (before PP) | 4.25 [3–7.5] | 4.5 [2–8.5]              | 7 [6–8]                      | 7 [6–7.5]                 | 3.5 [3.5–3.5]               | 3.5 [2–4.5]                 |                                        |
| ARR (mean [SD])      | 0.9 [1.1]   | 1.2 [1.1]                 | 1.0 [1.4]                     | 1.0 [1.0]                 | 0 [0]                        | 0.7 [1.2]                   |                                        |
| Disease status at treatment | relapse in 3 cases | relapse in 1 case | no relapse case | no relapse case | no relapse case | no relapse case | no relapse case |
| RRMS: SPMS           | 10: 6       | 8: 3                      | 2: 0                          | 0: 3                      | 1: 1                         | 1: 2                        |                                        |
| OCB (positive)       | 7/16        | 4/10                      | 0/1                           | 2/3                       | 0/2                          | 1/3                         |                                        |
| Maintenance treatment | GA          | 4                         | 4                             | 0                         | 0                            | 0                           |                                        |
|                      | IFN-b       | 1                         | 0                             | 0                         | 0                            | 1                           |                                        |
|                      | Fingolimod  | 1                         | 0                             | 0                         | 0                            | 0                           |                                        |
|                      | steroid     | 10                        | 10                            | 2                         | 2                            | 1                           | 2                                      |
|                      | IS          | 8                         | 7                             | 2                         | 3                            | 1                           | 1                                      |

Demographics of the patients with multiple sclerosis and healthy control subjects are described. No patients presented with clinical characteristics suggestive of neuromyelitis optica spectrum disorder or myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease. Anti-aquaporin 4 antibody and anti-MOG antibody were negative in all the 29 and 7 patients who were tested, respectively. Five patients, who were treated twice with IAPP at different time points, are shown here based on the information at the first time of the treatment. The blood sample was obtained only before the treatment for one patient who was treated with DFPP. Intravenous methylprednisolone treatment was performed after IAPP in 4 among the total of 17 treatment courses of responders, and in 4 among the total of 15 courses of nonresponders. Five responders and one nonresponder were treated with intravenous methylprednisolone before IAPP. One responder was treated with intravenous high-dose immunoglobulin after IAPP. Intravenous methylprednisolone treatment was performed after DFPP in 2 responders and 2 nonresponders. One responder and one nonresponder were treated with intravenous methylprednisolone before DFPP. One responder was also treated with intravenous high-dose immunoglobulin after DFPP. One responder and one nonresponder to IAPP were included in the analysis of B cell repertoire analysis (Fig 6E, F). Two responders and one nonresponder were included in B cell gene expression analysis (Fig 7).

ARR = annualized relapse rate; DFPP = double-filtration plasmapheresis; EDSS = Expanded Disability Status Scale; GA = glatiramer acetate; HC = healthy control; IAPP = immunoadsorption plasmapheresis; IFN-β = interferon-β; IS = immunosuppressant; OCB = oligoclonal bands; PP = plasmapheresis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary-progressive multiple sclerosis.
FIGURE 2: The frequencies of various immune cell subsets are not different between responders and non-responders before the treatment with IAPP. (A) Representative flow cytometry plots showing CXCR5+CD45RA−CD4+ follicular helper T cells. (B) The frequency of follicular helper T cells among memory CD4+T cells was analyzed in the peripheral blood of responder and non-responder patients to IAPP, before the treatment. The frequency was compared before and after the treatment. (C) Representative flow cytometry plots showing B cell subsets. (D) The frequency of B cells among mononuclear cells, and plasmablasts, transitional B cells, memory B cells, and naive B cells among CD19+ B cells were analyzed in the peripheral blood of responder and non-responder patients before IAPP treatment. (E) Representative flow cytometry plots showing NKT cells, NK cells, HLA-DR+ NK cells, and classical/intermediate/non-classical monocytes. (F) The frequency of NKT cells among CD3+ T cells, NK cells among CD3+CD19- non-T non-B cells, HLA-DR+ cells among NK cells, monocytes among CD3+CD19+CD56+ non-T non-B non-NK cells, and classical/intermediate/non-classical monocytes among all monocytes, were analyzed in the peripheral blood of responder and nonresponder patients to IAPP, before the treatment. Error bars represent the mean ± SD. IAPP = immunoadsorption plasmapheresis. [Color figure can be viewed at www.annalsofneurology.org]
Expressions of Inflammation-Related Genes in Th1 Cells Are Reduced After the Treatment With IAPP

At first, expression of IFN-γ receptor α (IFN-γRα) was evaluated to search for the mechanism underlying the correlation between the IFN-γ+ Th1 cell frequency and treatment response. We confirmed that the expression of IFN-γRα was significantly higher on monocytes than other immune cell subsets irrespective of treatment response (Fig 3A). However, it was not differentially expressed on any cell subsets between IAPP responders and nonresponders before the treatment (see Fig 3A). Moreover, the expression was not altered after IAPP (Fig 3B), implicating that IFN-γRα
is not involved in mediating the treatment response to IAPP.

Next, the gene expression profile of Th1 cells was investigated in order to detect a possible cell-intrinsic change by the treatment. We found that expressions of Th1-characteristic genes, IFNG, STAT1, and STAT4, were significantly decreased by the treatment (Fig 3C). In addition, the expression of TBX21, encoding T-bet, a central transcription factor of Th1 cells, tended to be decreased after IAPP (see Fig 3C). In contrast, no alteration related to IAPP treatment was detected in the expressions of some signature genes for Th2, Th17, and Treg cells (see Fig 3C). These gene profile data suggested that the IAPP treatment would reduce expression of inflammation-related genes in Th1 cells, which might be correlated with the link between IAPP responders and a higher Th1 cell frequency (see Fig 1B, F).

We further searched for a soluble factor that might be associated with the beneficial treatment effect of IAPP. Although none of 30 factors that we evaluated showed a predictive value, fibrinogen and GRO-α decreased, and SDF-1α and PDGF-BB increased after IAPP treatment (Fig 4A, B, data not shown). However, none of these factors had significant effect on the Th1-related genes at least in our experimental setting using primary CD4+ T cells (Fig 4C, D).

The Frequency of CD11c+ B Cells is Positively Correlated With Th1 Cell Frequency, and Reduced After IAPP Treatment

It has recently been reported that CD11c+ B cells are increased in the peripheral blood of patients with systemic lupus erythematosus (SLE), and the cells secrete a high amount of autoantibodies. CD11c+ B cells are characterized by a higher expression of TBX21, which could be induced by IFN-γ. Although it is generally thought that the primary mechanism of PP is to remove disease-relevant antibodies, we hypothesized that PP might influence the number or functions of this specific B cell population to mediate treatment effect. When the samples were divided based on the Th1 cell frequency, the frequency of CD11c+ B cell was significantly higher in the Th1-high group (Fig 5A). Individual analysis showed that the CD11c+ B cell frequency positively correlated with the Th1 cell frequency, and the expression of IFNG in Th1 cells (Fig 5B). CD21low B cells have been shown to be autoreactive and increased in rheumatoid arthritis, Sjogren syndrome, and idiopathic thrombocytopenic purpura. CD11c+ B cells had significantly lower expression of CD21 than the CD11c− counterpart, further supporting autoreactivity of CD11c+ B cell population (Fig 5C). The expression of CXCR5 was also decreased in

FIGURE 4: Fibrinogen decreases after treatment with IAPP. (A) The concentration of fibrinogen was measured in the plasma, and the concentrations of SDF-1α, GRO-α, and PDGF-BB were measured in the serum, from healthy controls and patients with multiple sclerosis before IAPP treatment. (B) Fibrinogen and GRO-α were decreased, and SDF-1α and PDGF-BB were increased after IAPP treatment. (C) CD4+ T cells were cultured with 0, 125, 250, and 4000 μg/ml of fibrinogen, for 2 days. The expressions of IFNG, STAT1, STAT4, and TBI, which are characteristic genes of Th1 cells, were measured in cultured CD4+ T cells in the presence of fibrinogen. Three independent experiments were combined with the values normalized to controls. There were 3 or 4 in each group. (D) CD4+ T cells were cultured in the presence of SDF-1α, GRO-α, or PDGF-BB, for 2 days. The expressions of IFNG, STAT1, STAT4, and TBI are shown. There were 3 in each group. An unpaired t test was used in A, and a paired t test was used in B for statistical analysis. Error bars represent the mean ± SD in A and C, and ± SEM in D. IAPP = immunoadsorption plasmapheresis. [Color figure can be viewed at www.annalsofneurology.org]
CD11c+ B cells (see Fig 5C), which is in line with the previous studies showing a relatively lower migratory potential of this subset to germinal centers.16,18,21 As expected from the correlation of Th1 cells and CD11c+ B cells (see Fig 5A, B), exogenous IFN-γ significantly increased the frequency of CD11c+ population among cultured naïve B cells, compared to IL-4, a Th2-characteristic cytokine (Fig 5D). This effect was similarly observed among healthy controls and patients with multiple sclerosis (see Fig 5D). Importantly, the frequencies of CD11c+ B cells and CD21−CD11c+ B cells decreased in the peripheral blood after IAPP treatment (Fig 5E). This observation can be in harmony with the results that IFNG expression by Th1 cells decreased after IAPP (see Fig 3C), and positively correlated with CD11c+ B cell frequency (see Fig 5B).

**CD11c+ B Cells Potently Produce Antibodies With Unique BCR Repertoire**

After observing the possible involvement of CD11c+ B cells in response to PP in multiple sclerosis, we next
FIGURE 6: CD11c+ B cells secrete a high amount of immunoglobulin characterized by BCR repertoire bias. (A) CD11c+, CD11+CD27-, and CD11c CD27- B cells were sorted and cultured for 7 days in the presence of IL-2, IL-21, BAFF, R848, and sCD40L. The amount of each immunoglobulin subset in the supernatant was measured. The average amounts of the 3 subsets were normalized to 1 for each sample. There were 6 patients with multiple sclerosis. (B) The concentration of each immunoglobulin subset in the serum. No differences were observed between responders and nonresponders before treatment (Figure legend continues on next page.)
evaluated antibody secretion by this population in comparison to other B cell subsets. All IgG subclasses and IgA were much more robustly produced by the CD11c^+ population than by CD11c^-CD27^- naive B cells (Fig 6A). Moreover, with regard to secretion of IgG2 and IgA, CD11c^+ B cells were even more efficient than CD11c^-CD27^- memory B cells (see Fig 6A). In addition, the frequency of plasmablasts/plasma cells positively correlated with CD11c^+ B cell frequency (see Fig 5B). Although the concentration of immunoglobulin in the serum did not predict treatment response (Fig 6B), all the immunoglobulin subsets were decreased by IAPP treatment, as expected (Fig 6C). No difference was found in the reduction rate between responders and nonresponders (Fig 6D). On the other hand, the reduction rate analysis (see Fig 6D) showed that IgG and IgM are more efficiently removed by IAPP treatment compared with IgA and IgE. The concentration of immunoglobulins may be different in the cerebrospinal fluid (CSF) between PP responders and nonresponders, because CD11c^+ B cells are more abundant there than in the peripheral blood, which needs further investigation.

Next, the BCR repertoire of IgG was analyzed in B cell populations that are classified based on the expression of CD11c and CD27. When the proportion of highly prevalent combinations of IgH chains (IgHV, IgHD, and IgHJ) was evaluated, it was notable that CD11c^+CD27^- B cells contained a larger number of expanded unique combinations, compared with CD11c^+CD27^+ or CD11c^-CD27^- B cells (Fig 6E). Supportive for this, the calculated index of clonal diversity appeared to be lower in CD11c^-CD27^- B cells, when the sequence of CDR3 was incorporated into the analysis (Fig 6F). Taken together, we postulate that the CD11c^+CD27^- B cell population is relatively more enriched for clonally expanded B cells, which are presumed to contain disease-relevant ones. Analysis of shared BCR repertoires detected no specific clonal similarity among these 3 B cell populations (data not shown).

CD11c^+ B Cells Are Transcriptionally Distinct from Other B Cell Subsets

To further evaluate the characteristics of CD11c^+ B cells, we analyzed the gene expression profiles of different B cell populations based on the expression of CD11c and CD27. First, these populations were clearly differentiated by principal component analysis, and most variable gene sets (Fig 7A, C). As expected, CD11c^+ B cells had higher expression of ITGAX, encoding CD11c (Fig 7B–D). Consistently with the data that CD11c^+ B cells are prevalent in the presence of IFN-γ (see Fig 5D), TBX21, a gene induced by IFN-γ, was highly expressed by CD11c^+ B cells (see Fig 7B–D). In addition, IFNGRI expression was relatively higher in CD11c^+ B cells compared to CD11c^-CD27^- memory B cells, indicating their enhanced responsiveness to IFN-γ (see Fig 7D). As expected from lower expression of CD21 (see Fig 5C), the corresponding gene, CR2, was relatively lower in CD11c^+ populations (see Fig 7C, D). Higher expression of CD80 and CD86 suggested that CD11c^+ B cells could exhibit higher co-stimulatory functions or maintain activated status (see Fig 7C, E).

TLR7 signaling, which is activated by single-stranded RNA, is critically involved in autoantibody-mediated diseases. The pivotal role of TLR7 ligands in autoantibody production has been described mainly in SLE, where autoantibodies respond to RNA- and DNA-containing autoantigens. However, the role of TLR signaling has been shown also in other autoimmune-mediated disorders, such as neuromyelitis optica. TLR7 was highly expressed in CD11c^+CD27^- B cells (see Fig 7C, F). This might partially contribute to their higher expression of TBX21 (see Fig 7B–D), as it was shown that IFN-γ and TLR7 stimulation synergistically induced T-bet expression in B cells. Additionally, TLR2 and TLR4 expressions were relatively higher in CD11c^+ B cells (see Fig 7C, F). Stimulation of these TLRs on B cells is known to induce the proliferation and differentiation of the B cells into plasma cells. These alterations were accompanied by a...
FIGURE 7: CD11c+ B cells are transcriptionally distinct from other B cell subsets. (A) Principal component analysis based on gene expression data of the 4 B cell populations (CD11c+/CD27+/CD27−/CD11c+CD27−) from 3 patients with multiple sclerosis. The expression data were obtained with nCounter system. (B) A Volcano plot showing differential gene expression of CD11c+ B cells, including CD11c+CD27− and CD11c+CD27+ cells, compared to CD11c−CD27+ B cells. (C) K-means clustering of 200 most variable genes detected by nCounter system. (D) The expression of genes that are involved in IFN-γ signaling and autoimmunity. (E) The expression of activation-related genes. (F) The expressions of TLR-related genes were detected by nCounter system. Error bars represent the mean ± SD.
reduced expression of TRAF5 in CD11c⁺CD27⁻ B cells (see Fig 7C, F). This is consistent with the fact that TRAF5 is a negative regulator of TLR7 signaling.²⁸ Moreover, higher expressions of IRAK4 and TRAF6 support the increased responsiveness of the CD11c⁺CD27⁻ B cells to the TLR stimulation, because these molecules would mediate downstream signaling of most TLRs, including TLR2, TLR4, and TLR7 (see Fig 7C, F).²⁹ Collective data in our study, consistent with a previous study for SLE,²¹ might suggest that CD11c⁺ B cells, especially CD11c⁺CD27⁻ B cells, stimulated by TLR signaling contribute to the development of autoantibody-mediated pathology in multiple sclerosis. In fact, disease exacerbation in multiple sclerosis is frequently observed during or after systemic infection, including potently TLR2- and TLR4-stimulating bacterial, and TLR7-stimulating viral infection.³⁰,³¹ Moreover, exacerbations associated with systemic infection are known to result in more sustained neurological deficits than other exacerbations.³²

In summary, this study has revealed that a subgroup of patients with multiple sclerosis who have relatively high frequencies of Th1 cells in the peripheral blood can be successfully treated with PP. In such patients, there was a correlative increase of CD11c⁺ B cells that might produce pathogenic autoantibody under the control by Th1 cells. The beneficial effects of PP are associated with decreased inflammatory characteristics of Th1 cells, and a decreased frequency of CD11c⁺ B cells, a potential source of autoantibodies. We therefore assume that removal of autoreactive immunoglobulins is not a sole mechanism of PP treatment for multiple sclerosis. The responders to PP could be predicted with the frequency of Th1 cells, which deserves further investigation to develop precision medicine in multiple sclerosis.

Discussion

Although PP may relieve disabling symptoms in a broad range of autoimmune neurological diseases, no beneficial effects of PP were observed in up to two thirds of patients with multiple sclerosis,²³,²⁷,²⁸ implying that such patients only take risks of potential complications, such as hemorrhage, infection, and deep venous thrombosis.³,²⁸ It was speculated that autoreactive immunoglobulins in the circulation are the main therapeutic target of PP.⁷,¹¹ However, immune cells and several plasma constituents, including cytokines, were shown to be also affected by PP, and the precise therapeutic mechanism has not yet been fully understood.³³,³⁴ This hinders reliable prediction of treatment response. Here, we propose a novel candidate predictor, Th1 cell frequency, which is supported by detailed analysis of immunological mechanism of PP (see Fig 1B, F). Most importantly, our study suggests that treatment response to PP is clearly different depending on immunological characteristics regarding Th1 cell - CD11c⁺ B cell axis in individual patients. This might be consistent with a previous finding that a subgroup of patients with distinct traits of pathology appears to benefit from PP.⁷,¹¹ PP was also beneficial for some patients with progressive disease, even more than 1 month after the last exacerbation (see the Table). Although previous studies failed to show the therapeutic efficacy of PP in progressive disease, it can be speculated that heterogeneity of immunological traits made it difficult to detect the benefit.² CD11c⁺ B cells are known to secrete a high amount of autoantibodies in patients with SLE.¹⁶ In addition, the frequency of CD11c⁺ B cells in the peripheral blood positively correlated with the titer of autoantibodies in the serum of the patients.¹⁶ Another study showed that CD11c⁺CD11b⁺ B cells were increased in lupus-prone mice, and depletion of these cells in vivo resulted in a reduced amount of autoantibodies.³⁵ We have revealed a positive correlation between the frequencies of CD11c⁺ B cells and Th1 cells (see Fig 5A, B). This is of particular interest considering that PP is effective in patients with a high Th1 cell frequency (see Fig 1B, F). We observed a higher frequency of CD11c⁺ cells after in vitro culture in the presence of IFN-γ compared to IL-4 (see Fig 5D). This is consistent with results from a previous report that IFN-γ and TLR7 stimulation synergistically promoted expression of CD11b and CD11c in B cells.²⁶ It was noted that CD11c⁺CD21⁻ B cells were increased in the peripheral blood of a subpopulation of patients with multiple sclerosis.²² Moreover, their frequency was further elevated in the CSF than in the blood, implying their involvement in the pathogenesis.²² Importantly, we found that both CD11c⁺ and CD11c⁺CD21⁻ B cells were reduced after PP (see Fig 5E). This might be attributable to a decreased expression of IFNG in Th1 cells after the treatment, because the expression positively correlated with the frequency of CD11c⁺ B cells (see Fig 5B).

CD11c⁺ B cells were also characterized by higher expression of TRB21, encoding T-bet (see Fig 7D). B cell-specific deletion of T-bet protects mice from murine lupus manifestations, including autoantibody production, renal damage, and rapid mortality,³⁶,³⁷ whereas IFN-γ is one of the key factors that induces T-bet expression in B cells.²⁶,³⁸,³⁹ B cell-specific Ifngr deletion abolished class-switched autoantibody production and systemic autoimmunity in a B cell-driven autoimmunity model.³⁸ IFN-γ was also reported to promote development of plasmablasts, and to enhance migratory capacity of B cells to the central nervous system (CNS).³⁹ Consistently, we found that the frequency of CD11c⁺ B cell positively
correlates with the frequency of plasmablasts/plasma cells in the peripheral blood (see Fig 5B). These data further support the pathogenic role of CD11c+B cells.

Our study showed that PP could remove fibrinogen (see Fig 4), which supposedly has a role in sustaining inflammatory pathology of multiple sclerosis, given its presence mainly at the active and chronic active lesions in the CNS of multiple sclerosis. In addition, the amount of fibrinogen in the plasma and the CSF correlates with the presence of active lesions and high cortical lesion load, respectively. Plasma-derived fibrinogen induces perivascular microglial clustering, and thereby mediates recruitment of T cells and macrophages, which may cause axonal damage in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. Although the pathological contribution of fibrinogen is mostly attributable to its interaction with CD11b, fibrinogen could bind CD11c and TLR4 as well. It is an open question whether fibrinogen directly affect CD11c+B cells.

Our study suggested that successful treatment response to plasmapheresis is not observed when Th1-CD11c+B cell axis is not working, whereas Th1 cell frequency is similar between responders and healthy controls. Although autoreactive B cells are enriched in the CD11c+ population, this population could be heterogeneous. This might be the case for Th1 cells in the context of Th1-CD11c+B cell axis, too. Further studies are needed to clarify possible functional difference of Th1-CD11c+B cell axis among responders, nonresponders, and healthy controls.

Although we focused on the antibody-related function of B cells, a number of recent studies suggested that other antibody-independent functions are highly relevant in the pathogenesis of multiple sclerosis, such as antigen presentation, co-stimulation of adjacent immune cells, and secretion of inflammatory cytokines. Our study indicated Th1 cell - CD11c+B cell axis is involved in responsiveness to PP, presumably mediated by the decrease of CD11c+B cells and removal of pathogenic immunoglobulins. We also showed that this B cell population is a potent producer of antibodies. However, these findings do not necessarily exclude other possible pathogenic roles of CD11c+B cells, which may also be related with response to PP. The target antigens of antibodies secreted from CD11c+B cells and their potential pathogenicity should be determined to address this issue. Besides, IL-4+CD4+Th2 cells and IL-10+CD4+T cells tended to be higher in responders (see Fig 1B). It is of interest to investigate the possible involvement of these populations in this context.

This study has some limitations, which could not be fully addressed. The treatment plan was determined by attending neurologists without randomization, although the neurologists were blinded to any laboratory results obtained by flow cytometer. All the patients had a history of insufficient response to treatment with high-dose steroids. These factors might have resulted in selection bias. Additional treatment to PP might have affected the results, although there was no significant difference regarding additional treatment between responders and nonresponders (see the Table). There were no secondary outcome parameters, such as magnetic resonance imaging (MRI) lesions included in this study. We could not identify the exact mechanism underlying PP-induced transcriptional change of Th1 cells, where further studies are warranted.

As CD11c+B cells appear to be involved in the pathogenesis of SLE, it is of great interest to explore whether our hypothesis about Th1 cell - CD11c+B cell axis could also be relevant for prediction of PP responses in other autoimmune neurological diseases. Besides, we and other research groups previously showed that gut microbiota is altered in patients with multiple sclerosis. We found that it is also significantly different between typical and atypical multiple sclerosis cases. Specific types of dysbiosis might be involved in the responsiveness to PP, which deserves further investigations in the future.

Acknowledgments
The authors are grateful to Chiharu Tomi for technical assistance. This research was supported by AMED under Grant Number JP19ek0109382; JSPS KAKENHI under Grant Number JP18K15473; Research on rare and intractable diseases, Health, Labor, and Welfare Sciences Research Grants, the Ministry of Health, Labour, and Welfare under Grant Number H26-nanchito(nan)-ippan-074, H29-nanchito(nan)-ippan-043; and Intramural Research Grant (25-4, 28-5, 1-5) for Neurological and Psychiatric Disorders of the National Center of Neurology and Psychiatry (NCNP), Japan.

Potential Conflicts of Interest
Y.L. had a joint research with Asahi Kasei Medical Co. Ltd., which manufactures the medical equipment that is used for participants in this study. T.Y. received grant support for research from Asahi Kasei Medical Co. Ltd. K.K., Y.L., and T.Y. have a pending patent in Japan for methods to collect data for prediction of response to plasmapheresis. All the other authors report no potential conflict of interest.
Author Contributions
K.K., Y.L., H.Y., W.S., D.T., M.M., Y.D., T.O., R.T., T.K., and T.Y. contributed to conception and design of the study. K.K., Y.L., H.Y., and T.Y. contributed to acquisition and analysis of data. K.K., Y.L., and T.Y. drafted a significant portion of the manuscript and figures.

References
1. Osman C, Jennings R, El-Ghariani K, Pinto A. Plasma exchange in neurological disease. Pract Neurol 2020;20:92–99.
2. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39:1143–1149.
3. Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878–886.
4. Magana SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011;68:870–878.
5. Koziolek MJ, Tampe D, Bahr M, et al. Immunoabsorption therapy in patients with multiple sclerosis with steroid-refractory optic neuritis. J Neuroimmunol 2012;249:90.
6. Schimrigk S, Faiss J, Kohler W, et al. Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoabsorption - observational multicenter study with 147 patients. Eur Neurol 2016;75:300–306.
7. Stork L, Ellenberger D, Beissbarth T, et al. Differences in the responses to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis. JAMA Neurol 2018;75:428–435.
8. Dorst J, Fangerau T, Taranu D, et al. Safety and efficacy of immunoabsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: a randomised, parallel-group, controlled trial. EClinicalMedicine 2019;16:98–106.
9. Lucchini C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.
10. Pittack SJ, McClelland RL, Achenbach SJ, et al. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry 2005;76:1693–1697.
11. Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579–582.
12. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
13. Kitaura K, Shin T, Matsutani T, Suzuki R. A new high-throughput sequencing method for determining diversity and similarity of T cell receptor (tcr) alpha and beta repertoires and identifying potential new invariant tcr alpha chains. BMC Immunol 2016;17:38.
14. Kitaura K, Yamashita H, Ayabe H, et al. Different somatic hypermutation levels among antibody subclasses disclosed by a new next-generation sequencing-based antibody repertoire analysis. Front Immunol 2017;8:389.
15. Ge SX, Son EW, Yao R. Idep: an integrated web application for differential expression and pathway analysis of ma- seq data. BMC Bioinformatics 2018;19:534.
16. Wang S, Wang J, Kumar V, et al. Il-21 drives expansion and plasma cell differentiation of autoreactive cd11c(high)-bet(+) b cells in sle. Nat Commun 2018;9:1758.
17. Obeng-Adjei N, Portugal S, Holla P, et al. Malaria-induced interferon-gamma drives the expansion of tbet(+) atypical memory b cells. PLoS Pathog 2017;13:e1006576.
18. Isnardi I, Ng YS, Menard L, et al. Complement receptor 2/cd21-human naive b cells contain mostly autoreactive unresponsive clones. Blood 2010;115:5026–5036.
19. Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive unresponsive cd21(−)/low b cells in sjogren’s syndrome-associated lymphoproliferation. Arthritis Rheum 2013;65:1085–1096.
20. Patuzzo G, Barbieri A, Tinazzi E, et al. Autoimmunity and infection in common variable immunodeficiency (cvid). Autoimmun Rev 2016;15:877–882.
21. Jenks SA, Cashman KS, Zumaquero E, et al. Distinct effector b cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 2018;49:725–739. e726.
22. Claes N, Fraussen J, Vanheusden M, et al. Age-associated b cells with proinflammatory characteristics are expanded in a proportion of multiple sclerosis patients. J Immunol 2016;197:4576–4583.
23. Lau CM, Broughton C, Tabor AS, et al. Rna-associated autoantigens activate b cells by combined b cell antigen receptor/toll-like receptor 7 engagement. J Exp Med 2005;202:1171–1177.
24. Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and tlr9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417–428.
25. Wilson R, Makuch M, Kienzler AK, et al. Condition-dependent generation of aquaporin-4 antibodies from circulating b cells in neuro-myelitis optica. Brain 2018;141:1063–1074.
26. Rubtsova K, Rubtsov AV, van Dyk LF, et al. T-box transcription factor t-bet, a key player in a unique type of b-cell activation essential for effective viral clearance. Proc Natl Acad Sci U S A 2013;110:E3216–E3224.
27. Genestier L, Taillandet M, Mondiere P, et al. Tlr agonists selectively promote terminal plasma cell differentiation of b cell subsets specialized in thymus-independent responses. J Immunol 2007;178:7779–7786.
28. Buchta CM, Bishop GA. Traf5 negatively regulates tlr signaling in b lymphocytes. J Immunol 2014;192:145–150.
29. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 2010;11:373–384.
30. Correale J, Fiol M, Gilmore W. The role of relapses in multiple sclerosis during systemic infections. Neurology 2006;67:652–659.
31. Steelman AJ. Infection as an environmental trigger of multiple sclerosis disease exacerbation. Front Immunol 2015;6:520.
32. Bullevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952–960.
33. Yeh JH, Wang SH, Chien PJ, et al. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur J Neurol 2009;16:1318–1322.
34. Soltész P, Aleksza M, Antal-Szalmas P, et al. Plasmapheresis modulates th1/th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmunity 2002;35:51–56.
35. Rubtsov AV, Rubtsova K, Fischer A, et al. Toll-like receptor 7 (tlr7)-
driven accumulation of a novel cd11c(+) b-cell population is impor-
tant for the development of autoimmunity. Blood 2011;118:1305–
1315.
36. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates igg class switching
and pathogenic autoantibody production. Proc Natl Acad Sci U S A
2002;99:5545–5550.
37. Rubtsova K, Rubtsov AV, Thurman JM, et al. B cells expressing the
transcription factor t-bet drive lupus-like autoimmunity. J Clin Invest
2017;127:1392–1404.
38. Jackson SW, Jacobs HM, Arkatkar T, et al. B cell ifn-gamma receptor
signaling promotes autoimmune germinal centers via cell-intrinsic
induction of bcl-6. J Exp Med 2016;213:733–750.
39. van Langelaar J, Rijvers L, Janssen M, et al. Induction of brain-
fiblinetrating t-bet-expressing b cells in multiple sclerosis. Ann Neurol
2019;86:264–278.
40. Vos CM, Geurts JJ, Montagne L, et al. Blood-brain barrier alterations
in both focal and diffuse abnormalities on postmortem mri in multi-
ple sclerosis. Neurobiol Dis 2005;20:953–960.
41. Lee NJ, Ha SK, Sati P, et al. Spatiotemporal distribution of fibrinogen
in marmoset and human inflammatory demyelination. Brain 2018;
141:1637–1649.
42. Miranda Acuna J, Hidalgo de la Cruz M, Ros AL, et al. Elevated
plasma fibrinogen levels in multiple sclerosis patients during relapse.
Mult Scler Relat Disord 2017;18:157–160.
43. Maglione R, Hametner S, Facchiano F, et al. Iron homeostasis, com-
plement, and coagulation cascade as csf signature of cortical lesions
in early multiple sclerosis. Ann Clin Transl Neurol 2019;6:2150–2163.
44. Davalos D, Ryu JK, Merlini M, et al. Fibrinogen-induced perivascular
microglial clustering is required for the development of axonal dam-
age in neuroinflammation. Nat Commun 2012;3:1227.
45. Ryu JK, Petersen MA, Murray SG, et al. Blood coagulation protein
fibrinogen promotes autoimmunity and demyelination via chemokine
release and antigen presentation. Nat Commun 2015;6:8164.
46. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macro-
phage chemokine secretion through toll-like receptor 4. J Immunol
2001;167:2887–2894.
47. Sandor N, Lukacsi S, Ungai-Salanki R, et al. Cd11c/cd18 dominates
adhesion of human monocytes, macrophages and dendritic cells
over cd11b/cd18. PLoS One 2016;11:e0163120.
48. Ryu JK, Rafalski VA, Meyer-Franke A, et al. Fibrin-targeting immuno-
therapy protects against neuroinflammation and neurodegeneration.
Nat Immunol 2018;19:1212–1223.
49. Li R, Patterson KR, Bar-Or A. Reassessing b cell contributions in mul-
tiple sclerosis. Nat Immunol 2018;19:696–707.
50. Jelcic I, Al Nimer F, Wang J, et al. Memory b cells activate brain-
homing, autoreactive cd4(+) t cells in multiple sclerosis. Cell 2018;
175:85–100. e123.
51. Miyake S, Kim S, Suda W, et al. Dysbiosis in the gut microbiota of
patients with multiple sclerosis, with a striking depletion of species
belonging to clostridia Xiva and iv clusters. PLoS One 2015;10:
e0137429.
52. Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut
microbiome in multiple sclerosis. Nat Commun 2016;7:12015.
53. Takewaki D, Suda W, Sato W, et al. Alterations of the gut ecological
and functional microenvironment in different stages of multiple scle-
rosis. Proc Natl Acad Sci U S A 2020;117:22402–22412.